Detalhe da pesquisa
1.
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
Lancet
; 393(10191): 2599-2612, 2019 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31178152
2.
Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.
BMC Cancer
; 18(1): 391, 2018 04 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29621991
3.
Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.
Health Technol Assess
; 24(40): 1-190, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32880572
4.
Syndromic surveillance using regional emergency medicine internet.
Ann Emerg Med
; 44(3): 242-6, 2004 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-15332066
5.
The public health dashboard: a surveillance model for bioterrorism preparedness.
J Public Health Manag Pract
; 10(3): 234-40, 2004.
Artigo
em Inglês
| MEDLINE | ID: mdl-15253519